Brought to you by:
Three-year VIVO results back ‘continued safety and effectiveness’ of Zilver Vena venous stent
Three-year results of the VIVO clinical study support the continued safety and effectiveness of the Zilver Vena venous stent (Cook Medical) in the treatment of symptomatic iliofemoral venous outflow obstruction, attendees at the Vascular Interventional Advances (VIVA) 2021 (Oct. 5–7) in Las Vegas.…
‘The future is very bright for venous valve replacement’
The progress of two “promising” new devices in the venous valve replacement space were outlined during a Vascular Annual Meeting (VAM) special session co-hosted by the American Venous Forum (AVF). Wednesday afternoon. Ellen Dillavou, MD, associate professor of vascular surgery…
VenoValve granted FDA Breakthrough Device designation
Hancock Jaffe Laboratories today (Wednesday, Aug. 4) announced that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation status to the company’s VenoValve device, a potential treatment option for chronic venous insufficiency (CVI). “We are very pleased to…